Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia

Efficacy of imatinib mesylate (STI571) t

Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia

✍ K. Miyachi; A. Ihara; R. W. Hankins; R. Murai; S. Maehiro; H. Miyashita 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 248 KB

Nilotinib treatment-associated periphera

Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

✍ Ayalew Tefferi; Louis Letendre 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

Letter to the editor: Lnterferon-alpha-2

Letter to the editor: Lnterferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia

✍ Suttorp's, Meinolf ;Suttorp, Meinolf ;Rister, Manfred ;Schmitz, Norbert 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Prediction of initial cytogenetic respon

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

✍ Mark W. Drummond; Tessa L. Holyoake 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

Prediction of initial cytogenetic respon

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

✍ Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Ke 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## BACKGROUND Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SC

Results of triple therapy with interfero

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

✍ Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)‐positive chronic myelogenous l